Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Niacin
Drug ID BADD_D01559
Description Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Indications and Usage For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
Marketing Status Prescription; Discontinued
ATC Code C04AC01; C10AD02
DrugBank ID DB00627
KEGG ID D00049
MeSH ID D009525
PubChem ID 938
TTD Drug ID Not Available
NDC Product Code 71740-201; 51407-268; 71741-020; 62175-322; 59746-380; 0074-3274; 25441-0095; 47335-613; 65162-323; 62331-016; 59746-387; 71741-047; 50268-584; 68180-222; 47335-614; 51407-267; 59746-381; 0074-3275; 59651-019; 63629-7193; 72919-420; 59651-018; 59651-020; 71740-001; 62175-320; 0074-3265; 68180-221; 33342-189; 51552-0559; 68180-223; 33342-187; 62704-0027; 47335-539; 65162-322; 65372-1194; 65162-321
Synonyms Niacin | Nicotinic Acid | 3-Pyridinecarboxylic Acid | 3 Pyridinecarboxylic Acid | Niacin Lithium Salt, Hemihydrate | Niacin Potassium Salt | Potassium Salt, Niacin | Niacin Sodium Salt | Sodium Salt, Niacin | Niacin Tartrate | Tartrate, Niacin | Niacin Copper (2+) Salt | Niacin Hydrochloride | Hydrochloride, Niacin | Niacin Iron (2+) Salt | Niacin Tosylate | Tosylate, Niacin | Niacin Zinc Salt | Nicamin | Nico-400 | Nico 400 | Nico400 | Nicobid | Nicocap | Nicolar | Nicotinate | Wampocap | Enduracin | Induracin | Niacin Calcium Salt | Lithium Nicotinate | Nicotinate, Lithium | Niacin Aluminum Salt | Aluminum Salt, Niacin | Niacin Ammonium Salt | Niacin Lithium Salt | Niacin Cobalt (2+) Salt | Niacin Magnesium Salt | Niacin Manganese (2+) Salt
Chemical Information
Molecular Formula C6H5NO2
CAS Registry Number 59-67-6
SMILES C1=CC(=CN=C1)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams19.02.03.001; 17.15.02.0010.000724%Not Available
Amylase increased13.05.01.009--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000724%
Angioedema23.04.01.001; 10.01.05.0090.000724%Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Blood bilirubin increased13.03.01.008--
Blood creatine phosphokinase increased13.04.01.0010.001447%
Blood glucose increased13.02.02.002--Not Available
Blood lactate dehydrogenase increased13.04.02.002--
Blood urea increased13.13.01.0060.000724%Not Available
Blood uric acid increased13.02.04.001--Not Available
Burning sensation17.02.06.001; 08.01.09.0290.001447%Not Available
Cough22.02.03.001--
Dermatitis allergic23.03.04.003; 10.01.03.0140.000724%Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.002171%
Drug hypersensitivity10.01.01.0010.036542%Not Available
Dry skin23.03.03.001--
Dyspnoea02.01.03.002; 22.02.01.004--
Eructation07.01.02.003--
Erythema23.03.06.0010.002894%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Feeling abnormal08.01.09.0140.000724%Not Available
Feeling hot08.01.09.0090.001085%Not Available
Flatulence07.01.04.002--
Flushing24.03.01.002; 08.01.03.025; 23.06.05.0030.012301%
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages